Tonix Pharmaceuticals Advances Lyme Disease Vaccine Candidate and CNS Programs Across Multi-Therapy Pipeline
SHERIDAN, WYOMING - April 14, 2026 - Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company developing therapies across central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases, disclosed a concentrated cluster of pipeline advances in late March 2026. The company presented Phase 1 data for its Lyme disease vaccine candidate TNX-4800 and outlined an adaptive Phase 2 field study design at the World Vaccine Congress Washington 2026. On March 26, Tonix confirmed the first participant dosed in a Phase 1 investigator-initiated pharmacodynamic study of TNX-1900, an intranasal potentiated oxytocin compound under evaluation for migraine and craniofacial pain. The overlapping disclosures reflect an active push across multiple therapeutic categories, with key data readouts expected later in 2026.